Tirzepatide 2.5 mg Injection: Your First Four Weeks on Mounjaro

Why does tirzepatide treatment always begin at 2.5 mg?

Tirzepatide works by activating two gut-hormone receptors simultaneously, GIP and GLP-1. That dual action is what makes it distinct from older single-pathway medicines, and it is also why the early weeks can feel intense for some people. Nausea, loose stools and tiredness are common after the first injection or after a dose increase; they tend to ease within a week or two as the body adapts. Starting at 2.5 mg keeps those early effects manageable. Think of it as the body's introduction to the medicine rather than the medicine working at full effect.

The UK Summary of Product Characteristics (the authoritative clinical document for Mounjaro) specifies 2.5 mg as the initiation dose for all adults, regardless of starting weight or BMI. There is no clinical justification for beginning at a higher strength, and doing so increases the risk of side effects without delivering better long-term results. After four weeks at 2.5 mg, a prescriber reviews tolerability and typically increases to the 5 mg dose, which is covered in detail on its own dedicated page including what to expect at that stage, continuing the stepwise titration toward the dose that produces meaningful weight reduction for that individual.

If you keep your pen in the fridge door (near the milk, where you'll notice it) and take your injection on the same day each week, that small routine is often enough to stay consistent through those first four weeks. Consistency at this stage matters more than the number on the pen.

What side effects are most common at the 2.5 mg starting dose?

The side-effect profile of tirzepatide is dominated by gastrointestinal symptoms, and the 2.5 mg initiation dose is specifically designed to reduce their severity. The most frequently reported effects include nausea, indigestion, constipation, diarrhoea and burping. Fatigue and mild headaches are also noted by some people in the early weeks. These effects are generally at their most noticeable in the first few days after each injection and settle as the week progresses.

One side effect worth knowing at any dose is pancreatitis, which is uncommon but serious. In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent risk with GLP-1 and dual-agonist medicines: severe, persistent stomach pain that may extend to the back, with or without vomiting, warrants urgent medical attention. That warning applies from the very first dose, not only at higher strengths.

Most people find the 2.5 mg phase the most straightforward part of treatment, precisely because the dose is low. If side effects are significant enough to affect daily life, the prescriber should know, titration timelines can be adjusted. Stopping without clinical guidance is not the right response, and the nume frequently asked questions page covers some of the most common concerns people raise in those first weeks.

Who receives the 2.5 mg tirzepatide injection, and does the starting dose ever change?

In the UK, the 2.5 mg starting dose applies to everyone beginning Mounjaro for weight management. The licensed threshold is a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, raised cholesterol, obstructive sleep apnoea, prediabetes or type 2 diabetes. Lower BMI thresholds can apply for people from certain ethnic backgrounds under UK guidance. BMI alone, though, is only part of the picture: a prescriber considers your full medical history, any medicines you take, and contraindications before confirming suitability.

There is no version of UK clinical guidance in which an adult starts Mounjaro above 2.5 mg. That consistency is deliberate, both NICE's appraisal of tirzepatide and the SmPC are explicit on this point. NICE technology appraisal TA1026 sets out the broader eligibility criteria for tirzepatide in England, including the BMI thresholds and comorbidity requirements that determine whether treatment is appropriate at all.

People transferring from another clinic sometimes ask whether they still need to start at 2.5 mg. If you are established on Mounjaro and have evidence of your current dose, a prescriber can review that and confirm your ongoing dose, you would not typically restart from scratch. If you are entirely new to tirzepatide, the 2.5 mg injection is where treatment begins, without exception. More detail on how the dose schedule works across all six strengths is covered on the tirzepatide injection dosage page.

How does the 2.5 mg phase fit into the full Mounjaro treatment journey?

The full licensed dose range for Mounjaro runs from 2.5 mg through to 15 mg in six steps. Most people move through the lower doses relatively quickly (typically in four-week intervals) and settle at the dose that produces good tolerability alongside meaningful weight reduction. That maintenance dose is different for different people; some find 7.5 mg or 10 mg the right level, while others eventually reach the 15 mg pen before finding their balance. The 2.5 mg phase is short in the context of a longer course of treatment, but it matters: rushing past it tends to increase early dropout rates.

Understanding the broader dose structure can help set realistic expectations at the outset. The tirzepatide injection doses overview explains the full titration schedule and what each step is designed to achieve. For anyone thinking about private treatment and wondering what it costs over that journey, the Mounjaro price comparison page sets out the UK cost context honestly.

If you are ready to find out whether Mounjaro is clinically suitable for you, a good first step is understanding the treatment in full. Our free consultation is reviewed the same day by a GPhC-registered prescriber (a real clinician, not automated screening) and there is no obligation to proceed. Check your eligibility and ask any questions before committing to anything.